http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories View More Recent Stories
-
Cancer Genetics (CGIX) Announces CEO Panna Sharma to Step Down; Appoints John Roberts Interim
-
Cancer Genetics, Inc. Chief Executive Officer Steps Down
-
Cancer Genetics Expands Its Industry-Leading Immuno-Oncology Panel, Complete::IO™, to be the Most Comprehensive for Immune Profiling & Monitoring
-
Cancer Genetics (CGIX) Secures Non-Dilutive Funding $1.1M from New Jersey Technology Business Tax Certificate Transfer Program
-
Cancer Genetics Receives Non-Dilutive Funding of $1.1 Million through New Jersey Technology Business Tax Certificate Transfer (NOL) Program
-
Cancer Genetics (CGIX) Announces New York State Approval for FDA-Approved Oncomine Dx Target Test by Thermo Fisher Scientific (TMO)
-
Cancer Genetics Receives New York State Approval for FDA-Approved Oncomine Dx Target Test by Thermo Fisher Scientific
-
Cancer Genetics advances understanding of immune response and measurement in lymphomas by combining PD-L1 expression analysis with RNA analysis
-
Cancer Genetics (CGIX) Prices $7M Registered Direct Offering of 3.5M Units
-
Cancer Genetics Prices $7 Million Registered Direct Offering
-
Cancer Genetics to Participate in Upcoming Investor Conferences
-
Cancer Genetics Initiates Partnership to Reduce Alarmingly Increasing Cancer Mortality Rates in India
-
Cancer Genetics (CGIX) Appoints Thomas Widmann to its Board of Directors
-
Cancer Genetics Appoints Renowned Biotech Entrepreneur Dr. Thomas F. Widmann to its Board of Directors
-
Cancer Genetics Reports Record Third Quarter 2017 Revenue and 134% Increase in Contracted Bookings from Major Biotech and Pharmaceutical Companies
-
Cancer Genetics to Present Insights to Advance Precision Medicine in Non-Small Cell Lung Cancer (NSCLC) at AMP Annual Meeting 2017
-
Cancer Genetics Named One of the Top 10 Drug Discovery & Development Solution Providers by Panel of Industry Experts at Pharma Tech Outlook
-
Cancer Genetics, Inc. to Host Panel Discussion on “The Convergence of Artificial Intelligence and Healthcare - New Developments in Precision Medicine” During the 3rd Annual Dawson James Small Cap
-
Cancer Genetics, Inc. to Present at the 2017 Disruptive Growth Company Showcase NYC on September 27th
-
Cancer Genetics, Inc. Announces 25th Contract Win to Provide Testing & Diagnostic Services for Combination Immuno-Oncology Clinical Trial
-
Cancer Genetics, Inc. to Host Conference Call to Discuss Strategic and Business Rationale of vivoPharm Acquisition
-
Cancer Genetics (CGIX) Announces Acquisition of vivoPharm for $12M
-
Cancer Genetics Announces Transformative and Accretive Acquisition of vivoPharm, a Global Oncology & Immuno-Oncology Discovery Services Company
-
Cancer Genetics, Inc. Announces Second Quarter 2017 Financial Results, Accretive Acquisition and Capital Raise
-
Cancer Genetics to Hold Second Quarter 2017 Earnings Call on Monday, August 14th
-
DIA Elects Cancer Genetics, Inc.’s John A. (Jay) Roberts as Chairman of DIA Board of Directors
-
Cancer Genetics, Inc. Acclaimed by Frost & Sullivan For North American Technology Innovation in Precision Oncology
-
Cancer Genetics (CGIX) Launches Companion Diagnostic for Lung Cancer Leveraging Thermo Fisher's Oncomine Dx Target Test
-
Cancer Genetics, Inc. Launches FDA-Approved Universal Companion Diagnostic for Lung Cancer Leveraging Thermo Fisher's Next Generation Sequencing Panel Oncomine Dx Target Test
-
Cancer Genetics, Inc. to Present at the 7th Annual LD Micro Invitational
-
Cancer Genetics (CGIX) Partners with Roche's Ventana Medical Systems
-
Cancer Genetics, Inc. Partners with Ventana Medical Systems, Inc., a member of the Roche Group, to Ensure Market Access to Predictive Biomarker Test for New Immuno-Oncology (IO) Therapy for Advanced B
-
Cancer Genetics, Inc. Announces 15% Revenue Increase in First Quarter of 2017 over 2016 on Strong Organic Growth While Continuing on Path to Profitability
-
Cancer Genetics (CGIX) Launches Multi-Gene Liquid Biopsy Test For Lung Cancer Patients
-
Cancer Genetics, Inc. Changes The Paradigm For Lung Cancer Monitoring – Launches Clinically Actionable, Multi-Gene, Liquid Biopsy Test For Lung Cancer Patients, Liquid::Lung-cfDNA™
-
Cancer Genetics to Hold First Quarter 2017 Earnings Call on Friday, May 12th
-
Cancer Genetics, Inc. to Present at The Pioneers 2017 Conference Presented by Joseph Gunnar & Co., LLC
-
Cancer Genetics, Inc. Launches a Unique, Industry-Leading Panel That Provides Comprehensive & Precise Information for Immuno-Oncology Therapy Assessment & Patient Monitoring
-
Cancer Genetics, Inc. is Selected by eFFECTOR Therapeutics to Provide Biomarker Discovery and Development Services for Novel Oncology Drugs
-
Cancer Genetics (CGIX) Confirms Partnership with Mendel Health Enabling Artificial Intelligence in Precision Medicine for Cancer Care
-
Cancer Genetics, Inc. and Mendel.ai Announce Strategic Partnership Enabling Artificial Intelligence in Precision Medicine to Drive Personalized Treatment and Accelerate Clinical Trial Matching for Can
-
Cancer Genetics, Inc. to Present at The MicroCap Conference on April 4th at 08:00 AM in New York City
-
Cancer Genetics, Inc. Announces Record Revenue for Fourth Quarter and Full-Year 2016 and Provides 2017 Business Update
-
Cancer Genetics to Report Fourth Quarter & Year End 2016 Earnings and Business Update on March 23
-
Cancer Genetics India Partners with CSIR-Centre for Cellular and Molecular Biology to Organize the 2nd Annual Next Generation Sequencing Conference in India
-
Cancer Genetics, Inc. to Receive $1.0 Million in Non-Dilutive Funding Through New Jersey Technology Business Tax Certificate Transfer Program
-
Cancer Genetics, Inc. Hereditary Breast & Ovarian Cancer Panel Selected by Global Biopharma to Power 1,000+ Patient Clinical Study
-
Cancer Genetics, Inc. to Present at the 2nd Annual Disruptive Growth & Healthcare Conference
-
Cancer Genetics, Inc. Launches Entry into Comprehensive Hereditary Cancer Testing for Breast & Ovarian Cancers, Addressing a $2.5 Billion Market
-
Cancer Genetics (CGIX), Lantern Pharma Announce Strategic Collaboration

